Cost-Effectiveness of Alirocumab for the Secondary Prevention of Cardiovascular Events after Myocardial Infarction in the Chinese Setting

• Egile Nagusiak: Zhe Liang (Egilea), Qi Chen (Egilea), Ruiqi Wei (Egilea), Chenyao Ma (Egilea), Xuehui Zhang (Egilea), Xue Chen (Egilea), Fang Fang (Egilea), Quanming Zhao (Egilea)
• Formatua: Liburua
• Argitaratua: Frontiers Media S.A., 2021-04-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Background: Proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab reduce ischemic events; however, the cost-effectiveness remains uncertain. This study sought to evaluate its economic value in patients with myocardial infarction (MI) from the Chinese healthcare perspective.Methods: A st...